Pharmacy Joe

MAY 1, 2024

Subscribe on iTunes , Android , or Stitcher The label of “penicillin allergic” usually sticks to a patient’s medical record forever. A 50 y/o male with an SSTI had an unknown allergy to penicillin, received a single dose of ceftriaxone in the ED and was then switched to piperacillin-tazobactam as an inpatient.

Inpatient 98

Inpatient Medical Records Documentation Labelling 98

Pharmacy Joe

OCTOBER 11, 2020

In this episode, I’ll discuss how to predict the pharmacotherapy needs of your patient and team during an inpatient medical emergency. This is when you do regular pharmacist things like drawing up and labeling medications, and calculating doses. This work is valuable because it frees a nurse up to be hands-on with a patient.

Inpatient 40

Inpatient Hospitals Labelling 40

Pharmacy Joe

NOVEMBER 29, 2020

To improve the data available in this patient population, investigators in Brazil completed a multicenter, randomized, open-label, noninferiority trial with 1000 patients comparing rivaroxaban with warfarin for patients with atrial fibrillation and a bioprosthetic mitral valve.

Inpatient 40

Inpatient Labelling Hospitals 40

Pharmacy Joe

OCTOBER 22, 2023

The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.

Hospitals 52

Hospitals Labelling Inpatient 52

Pharmacy Joe

OCTOBER 22, 2023

The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.

Hospitals 52

Hospitals Labelling Inpatient 52

Pharmacy Joe

FEBRUARY 26, 2025

The study was an open-label, multicenter, randomized controlled trial in 9 Australian Emergency Departments. Secondary outcomes included serious adverse events. There were no differences in serious adverse events between groups either. This difference was not statistically significant.

Hospitals 52

Hospitals Inpatient Documentation Labelling 52

Pharmacy Joe

AUGUST 21, 2022

Recently published in Lancet was a non-inferiority, open-label, multicentre, randomized trial that sought to clarify the safety of early antibiotic discontinuation in hematology patients with fever of unknown origin during chemotherapy-induced neutropenia.

Chemotherapy 52

Chemotherapy Inpatient Labelling 52